Please see Full Prescribing Information for LEQEMBI, including Boxed WARNING, at LEQEMBIPI.com and Important Safety Information in the pinned post.
If your patients experience any negative adverse events or have complaints related to LEQEMBI, please report to or direct them to Eisai Product Safety at 1-888-274-2378 or by email at ESI_Safety@eisai.com. This will enable Eisai to gather essential information for evaluating your report. Or, if you prefer, you may contact the U.S. Food and Drug Administration (FDA) by visiting www.fda.gov/medwatch or call 1-800-FDA-1088.
To learn about Eisai Patient Support for LEQEMBI, call 1-833-4-LEQEMBI (1-833-453-7362) or visit https://www.EisaiPatientSupport.com/HCP/LEQEMBI
For more information about LEQEMBI, register here for updates, https://www.LEQEMBIHCP.com/register
This content is intended for U.S. HCPs only. LEQEMBI is an Eisai and Biogen product and is not associated with any individual users.
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.LEQEMBIHCP.com
Leqembi® (Lecanemab-Irmb) Hcp Questions
Leqembi® (Lecanemab-Irmb) Hcp's website is https://www.LEQEMBIHCP.com
Leqembi® (Lecanemab-Irmb) Hcp's LinkedIn profile is https://www.linkedin.com/company/leqembihcp
Leqembi® (Lecanemab-Irmb) Hcp's industry is
Pharmaceutical Manufacturing
Leqembi® (Lecanemab-Irmb) Hcp's top competitors are
Kisunla™ (Donanemab-Azbt) Hcp,
Abbvie,
Acadia Pharmaceuticals Inc.,
Harrow,
Galderma,
Boehringer Ingelheim,
Tagrisso® (Osimertinib) Hcp,
Alzheimer's Disease International,
Biogen,
Eisai Us.
Leqembi® (Lecanemab-Irmb) Hcp's categories are Pharmaceutical Manufacturing
